CoR --- Cofactor R
The World's 4th Organic Redox Cofactor
A new cofactor that has been proven to be the most effective
CoR4Mito Inc has discovered and identified CoR, a new and unique transmembrane oxidoreductase that acts on a sulfur group of donors, with FAD as the Carrier/ Acceptor. This enzyme catalyzes the transfer of electrons from one molecule to another in the mitochondria.
CoR involves the Phase Transfer Property, transferring 2 electrons and multiple complicated catalyzed redox reactions including catalysis carbohydrate, fatty acid, and amino acid.
The required physiological Carrier/Acceptor of CoR is FAD. FAD is a more energetic oxidizing agent than NAD.
In contrast, PQQ, the world’s 3rd redox cofactor, has not yet identified its physiological carrier/acceptor even after eighty years of study.
CoR Technology presents a new medical frontier. We are currently seeking new funding for advancing our research and development needs.
The worldwide market has been secured
The company has filed a worldwide IP to protect CoR’s market.
It is a solution for all mitochondrial dysfunction diseases, including aging-related diseases and more.
CoR Technology was discovered from human study cases already, and then backward to prove scientific evidence, which is different from traditional drug discovery.
We are currently seeking strategic partners to further develop its unique, innovative intellectual property. The company has already established collaborative relationships with individual partners and universities to allow for more study and advancement in CoR Technology.
At this time, CoR4Mito Inc utilizes a virtual corporate model deployment strategy for its core intellectual property. The company is seeking to build relationships in order to further advance the development of its IP CoR Technology into the broader markets of drug development, supplements, food additives, nutrition, dietary foods, and more.
CoR Technology’s unique, innovative IP proposes a groundbreaking and globalized pharmaceutical and nutraceutical composition.
The company is open to exploring and entering into licensing agreements.
Welcome to contact us for further questions and information.
MEET OUR TEAM
Jerome Liang, Ph.D.